home / stock / tlt:cc / tlt:cc news

TLT:CC News and Press, Theralase Technologies Inc.

Stock Information
Company Name: Theralase Technologies Inc.
Stock Symbol: TLT:CC
Market: TSXVC
Website: theralase.com
Menu
Get TLT:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
TLT:CC - Theralase(R) Reports Complete Response with X-Ray-Activated Rutherrin(R) in Muscle Invasive Bladder Cancer Preclinical Study

Toronto, Ontario--(Newsfile Corp. - April 13, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (" Theralase® " or the " Company "), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe...
TLT:CC - Theralase(R) Closes $CAN 2.66 Million Financing

Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Theralase® Technologies Inc.  (TSXV: TLT) (OTCQB: TLTFF)  (" Theralase® " or the " Company "), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the ...

TLT:CC - Theralase(R) Discovers Further Mechanism on How Ruvidar(R) Inactivates Herpes Simplex Virus

Toronto, Ontario--(Newsfile Corp. - March 17, 2026) - Theralase® Technologies Inc. ( TSXV: TLT ) ( OTCQB: TLTFF ) (" Theralase® " or the " Company "), a clinical stage pharmaceutical company, dedicated to the research and development of energy-activated small molecules for the...

TLT:CC - Theralase(R) Closes $1.1 M Non-Brokered Private Placement

Toronto, Ontario--(Newsfile Corp. - March 10, 2026) - Theralase® Technologies Inc. ( TSXV: TLT ) ( OTCQB: TLTFF ) (" Theralase® " or the " Company "), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe ...
TLT:CC - Theralase(R) Demonstrates That X-Ray-Activated Rutherrin(R) Is Significantly More Effective than Radiation Alone in the Destruction of Muscle Invasive Bladder Cancer

Toronto, Ontario--(Newsfile Corp. - March 9, 2026) - Theralase® Technologies Inc.  (TSXV: TLT) (OTCQB: TLTFF)  (" Theralase® " or the " Company "), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for th...

TLT:CC - Light-Activated Ruvidar and Interferon Demonstrate Enhanced Efficacy

Theralase(R) Demonstrates Additive Anti-Cancer Effect in Bladder Cancer In-Vitro Model when Light-Activated Ruvidar(R) is Combined with Interferon Toronto, Ontario--(Newsfile Corp. - March 2, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (" Theralase® " or the " Com...

TLT:CC - Correcting and Replacing: Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress

This Press Release identifies that Dr. Kulkarni has participated in a medical advisory position for Theralase(R) in the past. Toronto, Ontario--(Newsfile Corp. - February 20, 2026) - Theralase® Technologies Inc.  (TSXV: TLT) (OTCQB: TLTFF)  (" Theralase® " or the " Company...
TLT:CC - Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress

Toronto, Ontario--(Newsfile Corp. - February 17, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (" Theralase® " or the " Company "), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and ef...

TLT:CC - Theralase(R) Bladder Cancer Clinical Data to be Presented at the 2026 American Urological Association Annual Meeting

Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Theralase® Technologies Inc.  (TSXV: TLT) (OTCQB: TLTFF)  (" Theralase® " or the " Company "), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the...

TLT:CC - Theralase(R) Provides Update on Bladder Cancer Clinical Study

Interim clinical data has exceeded the recommended guidelines of the International Bladder Cancer Group for complete response and duration of complete response Toronto, Ontario--(Newsfile Corp. - February 4, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF)  (" Theralase...
Next 10